SLOAN HARRY

Director Harry Sloan buys 100,000 DKNG shares at $21.85 for $2.2M; stock now down 56.6% from 52-week high of $53.49

Director Harry Sloan purchased 100,000 shares of DraftKings at $21.85 on 2026-02-17, increasing his holdings by 40.0% to 350,219 shares total for $2,185,000. The purchase occurs in a context of significant price weakness: the stock is down 28.8% over 30 days and 56.6% from its 52-week high of $53.49, now trading at $23.21. However, Sloan's historical open-market buying record across all tickers shows an average 90-day return of +199.2% (5 prior buys with 20.00% 90-day win rate), which is substantially stronger than his same-ticker DKNG history where his prior buy on 2025-11-11 delivered a 90-day return of -10.2%. The company's fundamentals show $1.1B quarterly revenue with +27.0% annual growth, though profitability remains challenged with a $-256.8M net loss and an outlier P/E of 2321.00. The confluence of depressed share price, material position increase, and the insider's stronger cross-ticker timing record versus weaker DKNG-specific outcomes warrants observation of whether this accumulation precedes a recovery or continues a downward trend.

Director Harry Sloan buys 25,000 DKNG shares at $30.30; holdings rise 11.1% to 249.7K; stock down -41.1% from 52-week high

Director Harry Sloan purchased 25,000 shares of DraftKings at $30.30 on 2025-11-11, increasing his holdings by 11.1% to 249.7K shares. The buy occurs at a price 41.1% below the 52-week high of $53.49 and represents a discrete open-market acquisition totaling $757.5K in capital. Sloan's cross-ticker track record shows 4 prior buys with an average 90-day return of +1047.5% and a 100% win rate, though his single prior DKNG trade (a June 2024 sell that returned +1.2% over 90 days) was not well-timed. The company itself carries material headwinds: it reported a $-256.8M net loss in its most recent fiscal year despite revenue growth of +30.1%, signaling the acquisition occurs amid losses, not profitability gains.

Director Harry Sloan buys 15,796 shares across 3 purchases (avg $12.78) while STRZ down -21.9% in 90 days amid -65.9% revenue decline.

Harry Sloan, a Director of STARZ, executed 3 separate purchases totaling 15,796 shares for $201,895.92 over August 19–21, raising his holdings by 59.7% from 26,464 to 42,260 shares. This occurs while the stock trades -37.2% below its 52-week high of $20.96 and has fallen -21.9% over both the 30-day and 90-day periods. The company is unprofitable, posting a net loss of $-42,500,000.00 in its latest quarter and annual revenue has contracted -65.9% year-over-year. A cluster pattern is present: 2 other insiders also bought within the past 14 days. The blended purchase price of $12.78 sits 3% below the current price of $13.17, indicating the purchases occurred near recent lows but ahead of modest recovery, though whether this reflects conviction or other motivations cannot be determined from price action alone.

Director Harry Sloan sells 250,000 DKNG shares for $9.5M, reducing stake by 50% amid unprofitability

Director Harry Sloan sold 250,000 shares (250.0K shares) at $38.15 on 2024-06-14, reducing his holdings from 500,000 shares to 250,000 shares, a net reduction of 50.0%. The sale occurred when DKNG was trading at 52-week high proximity; current price of $38.91 is -20.1% from the 52-week high of $48.68, suggesting the stock has declined significantly since the transaction date. The company's fundamentals show Revenue of $1,174,996,000.00 ($1.2B) in the latest quarter with strong Annual revenue growth of +63.6%, but this growth masks underlying unprofitability: the company posted Net income of $-142,568,000.00 ($-142.6M) and was unprofitable over its most recent full fiscal year. Sloan's cross-ticker track record shows 1 prior buy with an average 30d return of +1923.4%, but this historical positive outcome does not extend to visibility on his prior DKNG-specific activity or outcomes. The 50% reduction in his personal stake merits attention given the company's ongoing losses despite topline expansion.